alexa Surface Modification Of Epirubicin-loaded PLGA Nanoparticle With Biotinylated Chitosan Enhances Anti-cancer Efficacy In Breast Cancer Cells | 9737
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Translational & Personalized Medicine

Hongli Chen
Posters: Transl Med
DOI: 10.4172/2161-1025.S1.009
Abstract
Nanoparticle (NP) delivery systems in cancer therapies provide better penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison with conventional cancer therapies. This is to continue our earlier work on the poly(D,L-lactide-co-glycolide) (PLGA) NPs with biotinylated chitosan (Bio-CS) modification, the modified PLGA NPs were further used as an epirubicin (EPB) carrier to enhance cancer targeting activity and to overcome multidrug resistance (MDR) in adriamycin-resistance human breast cancer cell line (MCF-7/ADM). In this study, Bio-CS were synthesized and characterized. The degree of substitution (DS), as defined as the number of biotin per 100 anhydroglucose units of CS, was determined by 1 H-NMR and ICP. EPB loaded PLGA NPs were prepared by a solvent evaporation technique (W1/O/W2). The PLGA NPs surface was modified with Bio-CS by covalent binding. PLGA NPs of (231.4 ? 21.0) nm in diameter characterized by the laser light scattering technique, scanning electron microscopy are spherical and its drug encapsulation efficiency is (84.1 ? 3.4)%. Zeta potential of unmodified NP was measured to be negative -(21.21 ? 2.13) mV. The positive zeta potential of modified NPs reveals the presence of CS on the surface of the modified NPs. Modified NPs were characterized for surface chemistry by X-ray photoelectron spectroscopy (XPS) and Fourier transform infrared (FT-IR). The result showed that the N region corresponding to the primary amide of CS and the S region corresponding to the biotin, indicating that PLGA NPs were successfully surface- modified with Bio-CS. The 31% of surface DS biotin of Bio-CS modified PLGA NPs were determined and the value was (1.36 ? 0.34) μmol/100mg. In vitro drug release studies showed that Bio-CS modified NPs had many advantages, such as prolonged drug release property and decreased burst release in comparison to the unmodified NPs, and the modified NPs achieved relatively constant release kinetics. For cytotoxicity evaluation in vitro , the MCF-7/ADM cells were treated with the PLGA NP and Bio- CS modified NP with the EPB, respectively, at same concentration of 150 μg/mL, for 4, 24, 48 and 72 h. We found that Bio-CS modified NPs increased markedly EPB anti-cancer activity compared to the unmodified NPs. Flow cytometry and confocal laser scanning microscopy revealed that bio-CS-modified NPs exhibited greater extent of cellular uptake than unmodified NP and free EPB at 48 h. Moreover, increased levels of uptakes of CS-modified NPs in MCF-7/ADM cells and decreased cell viabilities were compared to the free EPB and PLGA NPs. In summary, the NPs by surface modification Bio-CS with significantly enhanced anti- cancer drug EPB delivery, increased drug efficacy, and thus this system will have great potential for breast cancer chemotherapy.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

streamtajm

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version